In an analysis of 209 DICER1‐carriers from the International PPB/DICER1 Registry and NCI DICER1 syndrome study, a nonsignificant excess of breast cancer, prostate cancer, and melanoma was observed compared with US cancer registry (SEER) data (Stewart et al., 2019). Here, DICER1 is linked to prostate cancer.